Skip to content

Jazz Pharmaceuticals JAZZ Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax

Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax at other companies

Baxter International logo
Baxter InternationalBAX
$0-100%
International Business Machines logo
International Business MachinesIBM
-$540.75M-224%
International Business Machines logo
International Business MachinesIBM
$167M+144%
Popular logo
PopularBPOP
Corebridge Financial logo
Corebridge FinancialCRBG
Deckers Outdoor Corporation logo
Deckers Outdoor CorporationDECK

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax?
Jazz Pharmaceuticals (JAZZ) reported other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax of $0 in Q1 2026.
How has Jazz Pharmaceuticals's other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax changed year-over-year?
Jazz Pharmaceuticals's other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax increased by 100.0% year-over-year, from -$100K to $0.
What is the long-term trend for Jazz Pharmaceuticals's other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax?
Over 3 years (2021 to 2025), Jazz Pharmaceuticals's other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax has grown at a -13.9% compound annual growth rate (CAGR), from $160K to $102K.
What does other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax mean?
The change in value of hedging instruments used to protect against future cash flow fluctuations.
How do you interpret other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax?
Reflects the effectiveness and market value changes of the company's risk management strategy regarding interest rates, commodities, or foreign exchange.
How does other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax compare across companies?
Varies significantly based on the company's treasury and risk management policies.